Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Michel White
Dr. Masip discussed the role of non invasive ventilation in patients with advanced and decompensated heart failure (HF). He showed that both continuous positive airway pressure ventilation (C-PAP) and non-invasive positive pressure ventilation (NIPPV) improve outcomes in patients receiving this treatment. However, there is no clear advantage to either of these modalities over the other. The key issue is to initiate treatment early, to optimise benefits. Dr. Mebazaa presented key differences between hemodialysis and ultrafiltration in patients with HF. The use of ultrafiltration is promising in this patient population, but future studies are needed to better identify the patients most likely to benefit from this therapy. Dr. Nanas outlined the beneficial effects of the early use of intra-aortic balloon pump in patients with cardiogenic shock. Unstable patients with cardiogenic shock caused by ischemic heart disease showed significantly greater benefits when treatment was initiated prior to the intervention. Dr. Mohr presented an elegant overview of the role of LV assist devices in advanced HF. Significant progress has been made in this field. Newer devices including those providing partial support are promising. Finally, Dr. Abraham presented the potential clinical utilities of implantable monitoring devices. Data from the FAST, HOMEOSTASIS and CHAMPION trials showed significant benefits in patients with severe heart failure using these devices. For example, in CHAMPION, a 38% reduction in hospitalisations for HF was reported. Additional data are needed to better select the populations most likely to benefit from these devices.
Devices for severe heart failure